

1 Physical pain recruits the nucleus accumbens during social distress in borderline personality disorder

2 *Supplementary Material*

3 **Supplementary Methods**

4 **Participant inclusion criteria**

5 All participants were right-handed as assessed by the Edinburgh scale (Oldfield, 1971). Exclusion
6 criteria included a lifetime history of severe neurological illnesses, a lifetime history of schizophrenia,
7 and a history of alcohol or drug abuse or dependence within the past 6 months, use of painkillers
8 within the last month, pregnancy, and presence of counter-indications for MRI scanning (mainly metal
9 in the body and claustrophobia).

10 **Questionnaires**

11 ***BSL-23 and BSL-Supplement***

12 The Borderline Symptom List short form (BSL-23), French version (Nicastro *et al.*, 2016), is a 23-item
13 self-rated scale which quantitatively assesses symptoms of BPD, based on the DSM-IV (American
14 Psychiatric Association, 2000). This is a unidimensional scale and items are rated on a 5-point Likert
15 scale from 0 (not at all) to 4 (very much).

16 In addition to the BSL-23, participants were also administered the BSL-Supplement which
17 measures the frequency of self-destructive behaviors (e.g. self-harming behaviors, binge eating,
18 substance use, etc.) (Bohus *et al.*, 2007). This questionnaire assesses 11 behaviors rated within last
19 week and ranging from 0 (not at all) to 4 (daily or more often) which are summed to obtain a global
20 score.

21 ***RSQ***

22 Griffin and Bartholomew (1994) developed the 30-item Relationship Scales Questionnaire (RSQ) to
23 assess a variety of attachment styles (Griffin and Bartholomew, 1994). It refers to only
24 partners/relationships. The RSQ involves having patients indicate the extent to which (1= *not at all*
25 *like me*, 5 = *very much like me*) they believe each of 30 statements best describes their feelings about

26 close relationships. A recent review (Kurdek, 2002) suggests that avoidance and anxiety emerge as the
27 most reliable factors from the RSQ, organizing a bi-dimensional attachment space.

28 **Experimental design**

29 **Modified Cyberball game**

30 Participants were told that they would be playing Cyberball with 4 different players (i.e. players A and
31 B, or players C and D) that would be standing outside of the scanner (Figure 1 main text). To ensure
32 that all participants believed they were playing with “real” other players, before the scanning session
33 they were shown a behavioral testing room filled with computers and told that this would be where
34 the other players would be playing from. Additionally, at the beginning of the scanning session, the
35 experimenter asked, “Player 1, are you ready?” which was followed by pre-recorded messages from
36 4 distinct female voices saying different variations of “Yes, I am ready/Yep, ready/Yes, let’s go”.

37 At the beginning of each block, the following message appeared “You will now be playing with
38 players A and B” or “You will now be playing with players C and D”. Unbeknownst to the participants,
39 players A and B represented the “inclusion” players while C and D represented the “exclusion” players.
40 Each block lasted approximately 43 seconds, including 12 throws. Because each block was relatively
41 short, during the exclusion condition, players C and D threw to the participant only 1 to 2 times (in
42 order to maximize the amount of exclusion inflicted) and conversely during the inclusion condition,
43 players A and B threw to each other only 1 to 2 times. The Cyberball and temperature stimuli
44 conditions were presented in pseudorandom order with never more than 2 sequential blocks of either
45 Cyberball condition. In total, each participant played 4 blocks of inclusion followed by a hot thermal
46 stimulation, 4 blocks of inclusion followed by a warm stimulation, 4 blocks of exclusion followed by a
47 hot stimulation, and 4 blocks of exclusion followed by a warm stimulation.

48 **Preselection of thermal stimuli**

49 Individual subjectively hot stimulation temperatures were determined using a multiple random
50 staircase (MRS) algorithm (Gracely *et al.*, 1988). Our MRS procedure consisted of two independent

51 staircases. Initial thermal stimulations for the two staircases were randomly assigned between 41 to
52 45°C and participants rated how painful the stimulation was on a 10-point Likert scale. Within each
53 staircase, stimulus temperature increased or decreased with steps of 2°C, while smaller changes of
54 0.5°C occurred following direction flips in the sequence. The staircases were set to switch around a
55 rating of 7/10 (i.e. 70% subjective pain rating). Participants underwent this thresholding procedure
56 twice. The first threshold was determined outside the scanner (approximately 1 hour before scanning)
57 and required each staircase to have 4 direction flips. A second, shorter thresholding was done inside
58 the scanner, just before the Cyberball game and required only 3 flips. If participants differed by more
59 than 1°C between the two thresholds, we used the mean of the two temperatures during Cyberball
60 scanning. None of our subjects was stimulated at a temperature above 52°C.

61 The thermal stimuli were delivered in the following way: participants first saw a 1 sec long
62 fixation cross, followed by the text string “Temperature is changing” and concomitant delivery of the
63 heat stimulation. The pain intensity scale was presented just after the 2 sec of plateau stimulation,
64 when the temperature started to return to baseline, and lasted for a maximum of 5 sec.

65 **MRI data acquisition and analysis**

66 **ART repair**

67 To account for residual movement artefacts after realignment, Artefact Detection Toolbox (ART;
68 <http://web.mit.edu/swg/software.htm>) was used. Specifically, an image was defined as an outlier
69 (artefact) image if the head displacement was greater than 0.2 mm in the x, y, or z direction, if the
70 rotational displacement was greater than 0.02 radians, from the previous image, or if the global mean
71 intensity in the image was greater than 9 standard deviations from the mean image intensity for the
72 entire scan. Any image that was identified as an outlier was entered into that participant’s first level
73 SPM model as a regressor of no interest. No participant had more than 5% of total outlier scans.

74 **Participant specific subjective pain threshold as a covariate**

75 In the main fMRI analysis of the manuscript, we added the individual stimulation temperatures as a
76 nuisance regressor to the full factorial GLM model in order to parse out any neural effects due to the
77 fact that BPD patients were stimulated at significantly higher temperatures during the hot stimulations
78 compared to the HCs. In order to check that this manipulation worked, we also created a full-factorial
79 GLM in the exact same way, except that we did not add this covariate. We then compared the
80 differences between the main effect of temperature (i.e. hot>warm) between each model.

81 The model without temperature regressor revealed that distributed network of regions involved in
82 pain processing (insula, cingulate cortex, somatosensory cortex, and thalamus) was activated. Adding
83 the participant specific subjective pain threshold to the fMRI GLM model captured all the neural
84 differences that were attributed to our hot (vs. warm), painful stimulations. Thus, we can reasonably
85 suggest that group differential activations reported in the main text were due to differences in
86 underlying neural mechanisms independent of the fact that the groups were stimulated at significantly
87 differing temperatures.

88 **Medication load**

89 We computed an index of medication load for each BPD participant based on the summation of the
90 different dosages of each medication. To do so, we first coded the dosage as absent (0), low (1) or
91 high (2) for each medication separately. For antidepressants, we used a previously employed approach
92 (Sackeim, 2001) that differentiates between 4 levels of dosages, which we then converted into low-
93 dose (levels 1 and 2) and high-dose (levels 3 and 4). For antipsychotic treatments, we converted the
94 doses into chlorpromazine dose equivalents, and coded as 0, 1 or 2, for no medication, up to mean
95 effective daily dose, or above the daily dose as defined by Davis and Chen (2004). Anxiolytic
96 (lorazepam and alprazolam) psychostimulant (methylphenidate) doses were similarly coded as 0, 1 or
97 2, with reference to the midpoint of the Physician's Desk Reference-recommended daily dose range.
98 Finally, we generated a composite measure of total medication load, reflecting dose and variety of

99 different medications taken, by summing all individual medication codes for each medication category
100 for each individual BPD participant.

101 To check for any potentially confounding effects of BPD medication status, we entered medication
102 load as a covariate to 2x2 repeated measures ANCOVAs with the within factors 'Cyberball Condition'
103 (inclusion, exclusion) x 'Stimulation Temperature' (hot, warm) in the BPD group using the beta
104 estimates extracted from each of the right NAcc and the left amygdala. Specifically, we were looking
105 for an interaction between medication load and signal change. Both ANCOVAs yielded non-significant
106 results for all 3-way (i.e. Medication Load by Cyberball Condition by Stimulation Temperature) and 2-
107 way interactions (i.e. Medication Load by Cyberball Condition and Medication Load by Stimulation
108 Temperature). All $p > 0.34$.

109

110 **Supplemental Discussion**

111 Comparison with the Bungert et al. (2015) study. Our findings did not replicate those of Bungert et al.
112 (2015) concerning the insula and amygdala activation (see main text). Our paradigm, although quite
113 similar to that used in Bungert et al. (2015), differed in a few key ways. First, we specifically only chose
114 to recruit patients with a documented history of SIBs (discussed in the main text). Additionally, we
115 stimulated our participants at much more painful stimulation temperatures (approximately 3.18°
116 higher), which may more closely approximate the pain of SIBs. Finally, in their fMRI model Bungert et
117 al. did not control for the fact that BPD patients were associated with stronger subjective pain
118 thresholds than HCs. Although this should not be problematic for interpreting those brain responses
119 reflective of subjective pain experiences (comparable between the two-groups), it could lead to biased
120 interpretation for those brain regions who are sensitive to the physical properties of the thermal
121 stimuli. In particular, the posterior insular cortex, which was found to be strongly implicated in BPD
122 pain sensitivity by Bungert et al., is held to be the first cortical output of thalamic nuclei sensitive to
123 thermoception and contribute in processing sensory components of pain (Craig *et al.*, 2000). This
124 opens the possibility that the effects provided by Bungert might be confounded by differential

125 temperatures used for eliciting pain. This is not the case of our study as we added individual
126 stimulation temperature as a covariate to our fMRI model, we demonstrated that it reliably captured
127 neural differences between the stimulation temperatures, including in the insula. Consequently, using
128 this approach, the results from the 3-way interaction that we report throughout the main text are
129 more likely due to underlying neural differences between the groups (BPDs vs. HCs) pertaining to
130 differential processing of painful stimuli in a specific emotional context, rather than to the groups
131 being stimulated at different temperatures.

132

133

134

135

136

137

138 **Supplemental References**

- 139 American Psychiatric Association (2000). *DSM-IV-TR*.
- 140 Bohus, M., Limberger, M.F., Frank, U., et al. (2007). Psychometric properties of the Borderline
141 Symptom List (BSL). *Psychopathology*, **40**, 126–32
- 142 Craig, A.D., Chen, K., Bandy, D., et al. (2000). Thermosensory activation of insular cortex. *Nature*
143 *Neuroscience*, **3**, 184–90
- 144 Davis, J.M., Chen, N. (2004). Dose response and dose equivalence of antipsychotics. *Journal of*
145 *clinical psychopharmacology*, **24**, 192–208
- 146 Gracely, R.H., Lota, L., Walter, D.J., et al. (1988). A multiple random staircase method of
147 psychophysical pain assessment. *Pain*, **32**, 55–63
- 148 Griffin, D., Bartholomew, K. (1994). The metaphysics of measurement: The case of adult attachment.
149 *Journal of personality and social psychology*, **67**, 17–52
- 150 Kurdek, L.A. (2002). On Being Insecure about the Assessment of Attachment Styles. *Journal of Social*
151 *and Personal Relationships*, **19**, 811–34
- 152 Nicastro, R., Prada, P., Kung, A.-L., et al. (2016). Psychometric properties of the French borderline
153 symptom list, short form (BSL-23). *Borderline Personality Disorder and Emotion Dysregulation*,
154 **3**, 4
- 155 Oldfield, R.C. (1971). The assessment and analysis of handedness: the Edinburgh inventory.
156 *Neuropsychologia*, **9**, 97–113
- 157 Sackeim, H.A. (2001). The definition and meaning of treatment-resistant depression. *The Journal of*
158 *clinical psychiatry*, **62 Suppl 1**, 10–17
- 159

160 Supplemental Tables

Table S1: Patient comorbidities and medication list						
Patient ID	Currently depressed	Psychiatric comorbidities	Antidepressant (daily dose)	Antipsychotic (dose in chlorpromazine equivalence)	Others (daily dose)	Medication load (antidepressant + antipsychotics + other)
BPD01	No	Bipolar disorder, ADHD, social phobia	Fluoxetine (40)	Olanzapine (100)	Methylphenidate (40)	5 (2+2+1)
BPD02	No	Social phobia				0 (0+0+0)
BPD03	Yes		Venlafaxine (150)	Quetiapine (25)	Oxazepam (1)	5 (2+1+1)
BPD04	Yes	ADHD, panic disorder				0 (0+0+0)
BPD06	Yes	ADHD			Methylphenidate (20)	1 (0+0+1)
BPD07	No	ADHD, social phobia, agoraphobia	Citalopram (10)			1 (1+0+0)
BPD08	Yes	Social phobia	Citalopram (20)			2 (2+0+0)
BPD09	Yes	ADHD, social phobia	Fluoxetine (20)			2 (2+0+0)
BPD10	No	Bipolar disorder, social phobia, panic disorder				0 (0+0+0)
BPD11	No	Bipolar disorder, ADHD, social phobia, agoraphobia, bulimia nervosa	Fluoxetine (20)	Quetiapine (25)	Oxazepam (1)	4 (2+1+1)
BPD12	No	Social phobia				0 (0+0+0)
BPD13	Yes		Fluoxetine (60)		Trazodone (100)	3 (2+0+1)
BPD14	Yes	Panic disorder				0 (0+0+0)
BPD15	No	Social phobia, PTSD	Fluoxetine (40)	Quetiapine (200)	Mirtazapine (7.5)	5 (2+2+1)
BPD17	Yes		Venlafaxine (225)			2 (2+0+0)
BPD20	No	ADHD	Fluoxetine (20)		Oxazepam (1)	3 (2+0+1)
BPD21	No					0 (0+0+0)
BPD22	No	Social phobia	Fluoxetine (20)	Quetiapine (50)		4 (2+2+0)

BPD23	No				Methylphenidate (20)	1 (0+0+1)
BPD24	No		Fluoxetine (20)			2 (2+0+0)
ADHD : Attentional Deficit and Hyperactivity Disorder; PTSD : Post Traumatic Stress Disorder						

161

162

	Group			
	BPD (N=20)		HC (N=23)	
	Mean	SD	Mean	SD
<i>Need Threat Scale</i>				
IN distress	9.05	2.60	6.59	1.44
EX distress	14.72	2.27	13.97	1.99
<i>Pain ratings (5-point Likert Scale)</i>				
Pain intensity				
IN hot	3.74	0.65	3.84	0.55
IN warm	1.11	0.25	1.43	0.60
EX hot	3.81	0.79	4.07	0.57
EX warm	1.10	0.25	1.52	0.71
Pain unpleasantness				
IN hot	3.63	1.13	4.04	0.64
IN warm	1.76	0.68	1.79	0.73
EX hot	3.60	1.12	4.29	0.56
EX warm	1.78	0.80	1.73	0.69
BPD=borderline personality disorder; HC=healthy controls; EX=exclusion, IN=inclusion; SD=standard deviation				

163

164

Table S3: Right NAcc mediation results																				
		Consequent Variables																		
		M ₁ (RSQ Anxiety)				M ₂ (RSQ Avoidance)				M ₃ (BDI)				Y (Right NAcc signal [15,8,-14])						
Antecedent Variables		Coeff.	SE	t	p	Coeff.	SE	t	p	Coeff.	SE	t	p	Coeff.	SE	t	p			
X (Group)	<i>a</i> ₁	10.16	1.16	8.76	<.001	<i>a</i> ₂	3.66	1.53	2.39	0.02	<i>a</i> ₃	22.99	1.71	13.48	<.001	<i>c'</i>	-0.46	0.77	-0.59	0.56
M ₁ (RSQ Anxiety)	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	<i>b</i> ₁	0.11	0.04	2.58	0.01
M ₂ (RSQ Avoidance)	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	<i>b</i> ₂	0.02	0.03	0.66	0.51
M ₃ (BDI)	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	<i>b</i> ₃	0.00	0.03	0.12	0.91
Constant	<i>i</i> _{M1}	9.39	0.79	11.87	<.001	<i>i</i> _{M2}	20.09	1.05	19.21	<.001	<i>i</i> _{M3}	1.61	1.16	1.38	0.17	<i>i</i> _Y	-1.77	0.78	-2.28	0.03
Path statistics		<i>R</i> ² =0.65				<i>R</i> ² =0.12				<i>R</i> ² =0.82				<i>R</i> ² =0.28						
		<i>F</i> (2,40)=76.66, <i>p</i> <.001				<i>F</i> (2,40)=5.71, <i>p</i> =.02				<i>F</i> (2,40)=181.66, <i>p</i> <.001				<i>F</i> (5,37)=3.61, <i>p</i> =.010						
Indirect effect of X on Y																				
		Coeff.	SE	LLCI	ULCI															
Total		1.24	0.60	0.13	2.53															
<i>a</i> ₁ <i>b</i> ₁ (RSQ Anxiety)		1.09	0.57	0.11	2.47															
<i>a</i> ₂ <i>b</i> ₂ (RSQ Avoidance)		0.08	0.11	-0.06	0.38															
<i>a</i> ₃ <i>b</i> ₃ (BDI)		0.08	0.57	-0.91	1.37															
BDI=Beck Depression Inventory, LLCI=lower limit confidence interval, M=mediator, RSQ=Relationship Scales Questionnaire, SE=Standard Error, ULCI=upper limit confidence interval																				

Table S4: t-contrasts of whole brain analysis ($p < 0.05$, FWE corrected) of physical pain administered following heightened social distress (elicited via Cyberball)					
Contrasts	Anatomic Region	Cluster size	MNI coordinates		
			x	y	z
Main effects					
Main effect of Cyberball Condition (EX>IN)	L Inferior Parietal	2208	-36	-34	43
			-24	-4	49
			-24	-55	64
	R Inferior Parietal	172	6	2	13
			-3	5	10
			-21	-4	13
	R Superior Parietal	347	21	-64	58
			15	-61	64
		36	-37	43	
Main effect of Cyberball Condition (IN>EX)	No significantly activated voxels				
Main effect of Stimulation Temperature (hot>warm)	No significantly activated voxels				
Main effect of Group (BPD>HC)	No significantly activated voxels				
Main effect of Group (HC>BPD)	No significantly activated voxels				
Interactions					
Group x Stimulation Temperature (BPD>HC; Hot>Warm)	No significantly activated voxels				
Group x Stimulation Temperature (HC>BPD; Hot>Warm)	No significantly activated voxels				
Group x Cyberball Condition (BPD>HC; EX>IN)	No significantly activated voxels				
Group x Cyberball Condition (HC>BPD; EX>IN)	No significantly activated voxels				